Descartes 88
Alternative Names: Descartes-88Latest Information Update: 28 Aug 2023
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 03 Jul 2023 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Cartesian Therapeutics pipeline, July 2023)
- 03 Jul 2023 Preclinical trials in Cancer in USA (Parenteral) (Cartesian Therapeutics pipeline, July 2023)